Published on December 1, 2009 at 5:15 AM
Hard to Treat Diseases' (HTDS; http://www.htdsmedical.com/) operating subsidiary Mellow Hope finalized contract details with one of the largest manufacturer of intravenous medication in India. This contract promises additional increase in revenues for Hard to Treat Diseases in the following quarters.
The contract between HTDS and the Indian company secures the supply of raw pharmaceutical material to the Indian pharmaceutical company in the range of about 1 million USD. Mellow Hope will be ready to release the shipments shortly. This contract is bound to strengthen Mellow Hope's sales and further increase the value of HTDS.
HTDS' CEO Terry Yuan said, "With our earlier, 4 million USD deal with Indian Hetero Ltd. and our H1N1 vaccine deal with Chile, this is another great news for HTDS. Our business has truly grown in past few months and the investors must appreciate our achievements. With the world growing smaller and smaller, the vaccination market and industry are bound to grow bigger. That's the global trend, and HTDS is definitely a part of it."
SOURCE Hard to Treat Diseases